Phio Pharmaceuticals Reports Positive Results in Skin Cancer Trial
TL;DR Summary
Phio Pharmaceuticals reports positive pathology results from its Phase 1b trial of the cancer therapeutic INTASYL PH-762, showing high tumor clearance rates and a favorable safety profile, indicating potential as a non-surgical treatment for skin cancers.
Topics:business#cancer-treatment#clinical-trial#healthcare#intasyl-ph-762#phio-pharmaceuticals#skin-cancer
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
5 min
vs 6 min read
Condensed
96%
1,027 → 36 words
Want the full story? Read the original article
Read on Newsfile